Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer.
Saved in:
| Title: | Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer. |
|---|---|
| Authors: | Rosser CJ; Clinical & Translational Research Program, University of Hawaii Cancer Center,Honolulu, Hawaii., Tikhonenkov S; Clinical & Translational Research Program, University of Hawaii Cancer Center,Honolulu, Hawaii., Nix JW; Department of Urology, University of Alabama, Birmingham, Alabama., Chan OTM; Clinical & Translational Research Program, University of Hawaii Cancer Center,Honolulu, Hawaii., Ianculescu I; ImmunityBio, Inc., Culver City, California., Reddy S; NantHealth Inc, Culver City, California.; ImmunityBio, Inc., Culver City, California., Soon-Shiong P; NantHealth Inc, Culver City, California. |
| Source: | Oncoimmunology [Oncoimmunology] 2021 May 03; Vol. 10 (1), pp. 1912885. Date of Electronic Publication: 2021 May 03. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: Electronic Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2162-402X |
|---|---|
| DOI: | 10.1080/2162402X.2021.1912885 |
